US2018280475A1PendingUtilityA1

Fibroblast growth factor-9 promotes hair follicle regeneration after wounding

59
Assignee: UNIV PENNSYLVANIAPriority: Nov 12, 2008Filed: Jun 8, 2018Published: Oct 4, 2018
Est. expiryNov 12, 2028(~2.3 yrs left)· nominal 20-yr term from priority
Inventors:George CotsarelisOh-Sang Kwon
A61P 35/00A61P 43/00A61Q 7/00A61P 17/14A61M 37/00A61K 8/64A61N 2005/1098A61K 45/06A61K 38/20A61K 38/1825A61M 2037/0007A61N 5/10A61P 17/00A61K 38/1712Y10S514/88A61K 38/18
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods for treating hair loss, treating, inhibiting, or suppressing a degenerative skin disorder, treating androgenetic alopecia (AGA), generating new hair follicles (HF), and increasing the size of existing HF. The methods comprise epidermal disruption or administration of wnt, and administration of a fibroblast growth factor-9 polypeptide or another compound that upregulates sonic hedgehog gene signaling.

Claims

exact text as granted — not AI-modified
1 . A method of treating hair loss in a subject comprising the steps of (a) disrupting the epidermis in the region of said hair loss in said subject and (b) administering a composition comprising a fibroblast growth factor-9 polypeptide to said subject. 
     
     
         2 .- 159 . (canceled) 
     
     
         160 . A method of treating hair loss in a subject, comprising stimulating in the subject one or more members of the sonic hedgehog (SHH) signaling pathway. 
     
     
         161 . A method for generating a hair follicle in the dermis of a subject, comprising stimulating in the subject one or more members of the sonic hedgehog (SHH) signaling pathway. 
     
     
         162 . A method for increasing hair follicle formation in the skin of a subject, comprising stimulating in the subject one or more members of the sonic hedgehog (SHH) signaling pathway. 
     
     
         163 . A method for treating an androgenetic alopecia (AGA) in a scalp of a subject, comprising stimulating in the subject one or more members of the sonic hedgehog (SHH) signaling pathway. 
     
     
         164 . The method of  claim 160 , wherein the stimulating step comprises administering to the subject a composition that stimulates one or more members of the SHH signaling pathway. 
     
     
         165 . The method of  claim 161 , wherein the stimulating step comprises administering to the subject a composition that stimulates one or more members of the SHH signaling pathway. 
     
     
         166 . The method of  claim 162 , wherein the stimulating step comprises administering to the subject a composition that stimulates one or more members of the SHH signaling pathway. 
     
     
         167 . The method of  claim 163 , wherein the stimulating step comprises administering to the subject a composition that stimulates one or more members of the SHH signaling pathway. 
     
     
         168 . The method of  claim 164 , wherein the composition inhibits Patched homolog 1 (PTCH1). 
     
     
         169 . The method of  claim 165 , wherein the composition inhibits Patched homolog 1 (PTCH1). 
     
     
         170 . The method of  claim 166 , wherein the composition inhibits Patched homolog 1 (PTCH1). 
     
     
         171 . The method of  claim 167 , wherein the composition inhibits Patched homolog 1 (PTCH1). 
     
     
         172 . The method of  claim 164 , wherein the composition inhibits Patched homolog 2 (PTCH2). 
     
     
         173 . The method of  claim 165 , wherein the composition inhibits Patched homolog 2 (PTCH2). 
     
     
         174 . The method of  claim 166 , wherein the composition inhibits Patched homolog 2 (PTCH2). 
     
     
         175 . The method of  claim 167 , the composition comprises inhibits Patched homolog 2 (PTCH2). 
     
     
         176 . The method of  claim 164 , wherein the member of the SHH signaling pathway is glioma-associated oncogene homolog 1 (GLI1). 
     
     
         177 . The method of  claim 165 , wherein the member of the SHH signaling pathway is glioma-associated oncogene homolog 1 (GLI1). 
     
     
         178 . The method of  claim 166 , wherein the member of the SHH signaling pathway is glioma-associated oncogene homolog 1 (GLI1). 
     
     
         179 . The method of  claim 167 , wherein the member of the SHH signaling pathway is glioma-associated oncogene homolog 1 (GLI1). 
     
     
         180 . The method of  claim 164 , wherein the composition comprises a glioma-associated oncogene homolog 1 (GLI) polypeptide, a biologically active fragment thereof, or a homolog thereof having the function of stimulating one or more members of the sonic hedgehog (SHH) signaling pathway. 
     
     
         181 . The method of  claim 165 , wherein the composition comprises a glioma-associated oncogene homolog 1 (GLI) polypeptide, a biologically active fragment thereof, or a homolog thereof having the function of stimulating one or more members of the sonic hedgehog (SHH) signaling pathway. 
     
     
         182 . The method of  claim 166 , wherein the composition comprises a glioma-associated oncogene homolog 1 (GLI) polypeptide, a biologically active fragment thereof, or a homolog thereof having the function of stimulating one or more members of the sonic hedgehog (SHH) signaling pathway. 
     
     
         183 . The method of  claim 167 , wherein the composition comprises a glioma-associated oncogene homolog 1 (GLI) polypeptide, a biologically active fragment thereof, or a homolog thereof having the function of stimulating one or more members of the sonic hedgehog (SHH) signaling pathway. 
     
     
         184 . The method of  claim 180 , wherein the amino acid sequence of the GLI1 polypeptide is as set forth in SEQ ID NO: 5. 
     
     
         185 . The method of  claim 181 , wherein the amino acid sequence of the GLI1 polypeptide is as set forth in SEQ ID NO: 5. 
     
     
         186 . The method of  claim 182 , wherein the amino acid sequence of the GLI1 polypeptide is as set forth in SEQ ID NO: 5. 
     
     
         187 . The method of  claim 183 , wherein the amino acid sequence of the GLI1 polypeptide is as set forth in SEQ ID NO: 5. 
     
     
         188 . The method of  claim 164 , wherein the member of the SHH signaling pathway is glioma-associated oncogene homolog 2 (GLI2). 
     
     
         189 . The method of  claim 165 , wherein the member of the SHH signaling pathway is glioma-associated oncogene homolog 2 (GLI2). 
     
     
         190 . The method of  claim 166 , wherein the member of the SHH signaling pathway is glioma-associated oncogene homolog 2 (GLI2). 
     
     
         191 . The method of  claim 167 , wherein the member of the SHH signaling pathway is glioma-associated oncogene homolog 2 (GLI2). 
     
     
         192 . The method of  claim 164 , wherein the composition comprises a glioma-associated oncogene homolog 2 (GLI2) polypeptide, a biologically active fragment thereof, or a homolog thereof. 
     
     
         193 . The method of  claim 165 , wherein the composition comprises a glioma-associated oncogene homolog 2 (GLI2) polypeptide, a biologically active fragment thereof, or a homolog thereof. 
     
     
         194 . The method of  claim 166 , wherein the composition comprises a glioma-associated oncogene homolog 2 (GLI2) polypeptide, a biologically active fragment thereof, or a homolog thereof. 
     
     
         195 . The method of  claim 167 , wherein the composition comprises a glioma-associated oncogene homolog 2 (GLI2) polypeptide, a biologically active fragment thereof, or a homolog thereof. 
     
     
         196 . The method of  claim 192 , wherein the amino acid sequence of the GLI2 polypeptide is as set forth in SEQ ID NO: 6. 
     
     
         197 . The method of  claim 193 , wherein the amino acid sequence of the GLI2 polypeptide is as set forth in SEQ ID NO: 6. 
     
     
         198 . The method of  claim 194 , wherein the amino acid sequence of the GLI2 polypeptide is as set forth in SEQ ID NO: 6. 
     
     
         199 . The method of  claim 195 , wherein the amino acid sequence of the GLI2 polypeptide is as set forth in SEQ ID NO: 6. 
     
     
         200 . The method of  claim 164 , wherein said administering is via topical administration. 
     
     
         201 . The method of  claim 165 , wherein said administering is via topical administration. 
     
     
         202 . The method of  claim 166 , wherein said administering is via topical administration. 
     
     
         203 . The method of  claim 167 , wherein said administering is via topical administration. 
     
     
         204 . The method of  claim 164 , wherein said administering is via subepidermal administration. 
     
     
         205 . The method of  claim 165 , wherein said administering is via subepidermal administration. 
     
     
         206 . The method of  claim 166 , wherein said administering is via subepidermal administration. 
     
     
         207 . The method of  claim 167 , wherein said administering is via subepidermal administration. 
     
     
         208 . The method of  claim 164 , wherein the subject is a human. 
     
     
         209 . The method of  claim 165 , wherein the subject is a human. 
     
     
         210 . The method of  claim 166 , wherein the subject is a human. 
     
     
         211 . The method of  claim 167 , wherein the subject is a human. 
     
     
         212 . The method of  claim 164 , wherein the subject has hair loss. 
     
     
         213 . The method of  claim 165 , wherein the subject has hair loss. 
     
     
         214 . The method of  claim 166 , wherein the subject has hair loss. 
     
     
         215 . The method of  claim 212 , wherein said hair loss is due to androgenetic alopecia (AGA). 
     
     
         216 . The method of  claim 213 , wherein said hair loss is due to androgenetic alopecia (AGA). 
     
     
         217 . The method of  claim 214 , wherein said hair loss is due to androgenetic alopecia (AGA). 
     
     
         218 . The method of  claim 215 , wherein the AGA is male pattern baldness or female pattern baldness. 
     
     
         219 . The method of  claim 216 , wherein the AGA is male pattern baldness or female pattern baldness. 
     
     
         220 . The method of  claim 217 , wherein the AGA is male pattern baldness or female pattern baldness. 
     
     
         221 . The method of  claim 167 , wherein the AGA is male pattern baldness or female pattern baldness. 
     
     
         222 . The method of  claim 212 , wherein said hair loss is due to skin injury. 
     
     
         223 . The method of  claim 213 , wherein said hair loss is due to skin injury. 
     
     
         224 . The method of  claim 214 , wherein said hair loss is due to skin injury. 
     
     
         225 . The method of  claim 212 , wherein said hair loss is in the scalp or eyebrow of said subject. 
     
     
         226 . The method of  claim 213 , wherein said hair loss is in the scalp or eyebrow of said subject. 
     
     
         227 . The method of  claim 214 , wherein said hair loss is in the scalp or eyebrow of said subject. 
     
     
         228 . The method of  claim 167 , wherein said AGA is in the scalp or eyebrow. 
     
     
         229 . The method of  claim 212 , wherein said hair loss is in scarred skin tissue of said subject. 
     
     
         230 . The method of  claim 213 , wherein said hair loss is in scarred skin tissue of said subject. 
     
     
         231 . The method of  claim 214 , wherein said hair loss is in scarred skin tissue of said subject. 
     
     
         232 . The method of  claim 212 , wherein the method further comprises disrupting the epidermis in the region of hair loss in the subject. 
     
     
         233 . The method of  claim 213 , wherein the method further comprises disrupting the epidermis in the region of hair loss in the subject. 
     
     
         234 . The method of  claim 214 , wherein the method further comprises disrupting the epidermis in the region of hair loss in the subject. 
     
     
         235 . The method of  claim 167 , wherein the method further comprises disrupting the epidermis in the region of AGA in the subject. 
     
     
         236 . The method of  claim 232 , wherein said disrupting is performed 3-12 days prior to administering the composition to the subject. 
     
     
         237 . The method of  claim 233 , wherein said disrupting is performed 3-12 days prior to administering the composition to the subject. 
     
     
         238 . The method of  claim 234 , wherein said disrupting is performed 3-12 days prior to administering the composition to the subject. 
     
     
         239 . The method of  claim 235 , wherein said disrupting is performed 3-12 days prior to administering the composition to the subject. 
     
     
         240 . The method of  claim 232 , wherein said disrupting is performed by exposing the region of said hair loss to a mechanical or chemical stimulus. 
     
     
         241 . The method of  claim 233 , wherein said step of disrupting is performed by exposing the region of said hair loss to a mechanical or chemical stimulus. 
     
     
         242 . The method of  claim 234 , wherein said disrupting is performed by exposing the region of said hair loss to a mechanical or chemical stimulus. 
     
     
         243 . The method of  claim 235 , wherein said step of disrupting is performed by exposing the region of said AGA to a mechanical or chemical stimulus. 
     
     
         244 . The method of  claim 232 , wherein said disrupting is performed by exposing the region of said hair loss to radiation. 
     
     
         245 . The method of  claim 233 , said step of disrupting is performed by exposing the region of said hair loss to radiation. 
     
     
         246 . The method of  claim 234 , wherein said disrupting is performed by exposing the region of said hair loss to radiation. 
     
     
         247 . The method of  claim 235 , wherein said step of disrupting is performed by exposing the region of said AGA to radiation.

Join the waitlist — get patent alerts

Track US2018280475A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.